PMC:7047369 / 9053-9146 JSONTXT

{"target":"https://pubannotation.org/docs/sourcedb/PMC/sourceid/7047369","sourcedb":"PMC","sourceid":"7047369","source_url":"https://www.ncbi.nlm.nih.gov/pmc/7047369","text":"Phase 1 trials for safety and immunogenicity in human populations are likely within 3 months.","tracks":[{"project":"LitCovid-PubTator","denotations":[{"id":"115","span":{"begin":48,"end":53},"obj":"Species"}],"attributes":[{"id":"A115","pred":"tao:has_database_id","subj":"115","obj":"Tax:9606"},{"subj":"115","pred":"source","obj":"LitCovid-PubTator"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}]},{"project":"LitCovid-PMC-OGER-BB","denotations":[{"id":"T145","span":{"begin":30,"end":44},"obj":"BV_15"},{"id":"T144","span":{"begin":48,"end":53},"obj":"SP_6;NCBITaxon:9606"}],"attributes":[{"subj":"T145","pred":"source","obj":"LitCovid-PMC-OGER-BB"},{"subj":"T144","pred":"source","obj":"LitCovid-PMC-OGER-BB"}]},{"project":"LitCovid-PD-CLO","denotations":[{"id":"T57","span":{"begin":48,"end":53},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_9606"}],"attributes":[{"subj":"T57","pred":"source","obj":"LitCovid-PD-CLO"}]},{"project":"LitCovid-sentences","denotations":[{"id":"T66","span":{"begin":0,"end":93},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"attributes":[{"subj":"T66","pred":"source","obj":"LitCovid-sentences"}]}],"config":{"attribute types":[{"pred":"source","value type":"selection","values":[{"id":"LitCovid-PubTator","color":"#93eca6","default":true},{"id":"LitCovid-PMC-OGER-BB","color":"#ec9399"},{"id":"LitCovid-PD-CLO","color":"#93b3ec"},{"id":"LitCovid-sentences","color":"#cdec93"}]}]}}